Chronic graft versus host disease affecting the liver is a challenging complication that can develop after receiving donor stem cells to treat blood disorders or cancers, requiring careful attention to both the immediate symptoms and long-term management strategies.

Understanding Treatment Goals and Approaches

When chronic graft versus host disease affects the liver after an allogeneic stem cell transplant, treatment focuses on several important goals. The primary aim is to control the immune response that causes donor cells to attack liver tissue, while also managing symptoms such as jaundice, elevated liver enzymes, and fatigue. Treatment success depends on balancing the suppression of this harmful immune activity against the need to maintain enough immune function to fight infections and prevent cancer relapse^[1].

The approach to treating hepatic chronic graft versus host disease varies significantly based on how severe the liver involvement is, which other organs are affected, and how each patient responds to therapy. Some patients may have mild liver dysfunction that can be managed with careful monitoring and adjustments to medications, while others face more serious liver damage requiring intensive immunosuppressive treatment. The stage of disease and the patient’s overall health condition play crucial roles in determining the most appropriate treatment strategy^[6].

Medical societies have established standard treatments approved for chronic graft versus host disease, but researchers continue to explore new therapies through clinical trials. These investigations aim to find more effective treatments with fewer side effects, offering hope for patients who do not respond adequately to current options. Understanding both established therapies and emerging treatments helps patients and healthcare providers make informed decisions about care^[3].

Standard Treatment Approaches

Corticosteroids, particularly prednisone and methylprednisolone, form the foundation of standard treatment for chronic graft versus host disease affecting the liver. These powerful medications work by broadly suppressing the immune system to reduce the inflammatory attack on liver tissue. Doctors typically start patients on corticosteroid therapy when laboratory tests show elevated liver enzymes or when patients develop jaundice, which appears as yellowing of the skin and eyes. The initial dose depends on disease severity, but patients often receive doses in the range of one to two milligrams per kilogram of body weight daily^[6].

The duration of corticosteroid treatment varies considerably among patients. Those who respond well to initial therapy may have their doses gradually reduced over several months, with the goal of tapering to the lowest effective dose or eventually stopping the medication entirely. However, many patients require treatment for one to three years or even longer. The median time for resolution of symptoms can extend to 30 to 42 days from the start of treatment, though complete recovery of liver function may take much longer^[8].

Long-term corticosteroid use carries significant risks that patients and doctors must carefully monitor. These medications can cause bone density loss leading to osteoporosis, increase blood sugar levels potentially causing diabetes, promote weight gain, elevate blood pressure, increase infection risk due to immune suppression, and cause muscle weakness particularly in the large muscles of the hips and thighs. Patients may also experience mood changes, difficulty sleeping, and increased appetite. Because of these potential complications, healthcare teams work to use the minimum effective dose and may add other medications to allow steroid reduction^[12].

Calcineurin inhibitors, including cyclosporine and tacrolimus, represent another cornerstone of treatment for hepatic chronic graft versus host disease. These medications work differently than corticosteroids by specifically blocking certain signals that activate immune cells. Cyclosporine, used for decades in transplant medicine, inhibits the production of substances that promote immune cell activation. Tacrolimus acts through a similar mechanism but is often considered more potent. Doctors frequently combine these agents with corticosteroids as part of initial therapy^[8].

When using cyclosporine, doctors monitor blood levels carefully to maintain therapeutic concentrations, typically keeping levels above 200 nanograms per milliliter. Tacrolimus also requires close monitoring through blood tests to ensure adequate dosing while avoiding toxicity. Both medications can affect kidney function, raise blood pressure, and increase the risk of infections. Patients taking calcineurin inhibitors need regular blood work to check kidney function, drug levels, and signs of other complications^[8].

The combination of a calcineurin inhibitor with short-course methotrexate represents a standard prophylactic regimen aimed at preventing graft versus host disease from developing in the first place. While this approach helps many patients, breakthrough disease can still occur, necessitating additional or alternative treatments. When chronic graft versus host disease does develop despite prophylaxis, doctors often continue the calcineurin inhibitor while adding corticosteroids and potentially other immunosuppressive agents^[8].

Additional immunosuppressive agents may be added when initial therapy proves insufficient. Mycophenolate mofetil inhibits the production of new immune cells by blocking a specific enzyme needed for cell division. Sirolimus, another medication that blocks immune cell activation through a different pathway than calcineurin inhibitors, offers an alternative or additional option. Both medications can be combined with corticosteroids and calcineurin inhibitors, though careful monitoring for side effects and drug interactions is essential^[8].

Some patients benefit from extracorporeal photopheresis, an innovative treatment approach that involves collecting white blood cells from the patient’s blood, treating them with a light-sensitive medication called 8-methoxypsoralen, exposing them to ultraviolet light, and then returning them to the body. This process makes the treated cells susceptible to programmed cell death, which can help reduce the immune attack on organs including the liver. The procedure is typically performed on consecutive days every two to four weeks. While it requires specialized equipment and expertise, extracorporeal photopheresis can be particularly helpful for patients who cannot tolerate high doses of systemic medications or who have disease that has not responded to standard treatments^[8].

Treatment in Clinical Trials

Researchers are actively investigating several promising new medications for chronic graft versus host disease through clinical trials conducted in the United States, Europe, and other locations worldwide. These studies aim to identify treatments that work better than current options or cause fewer side effects. Participation in clinical trials offers patients access to cutting-edge therapies while contributing to medical knowledge that may help future patients^[13].

Ruxolitinib, a medication that blocks proteins called Janus kinases (JAK), has shown considerable promise in treating chronic graft versus host disease. These proteins play a crucial role in transmitting signals that activate immune cells and promote inflammation. By blocking JAK proteins, ruxolitinib can reduce the immune attack on organs including the liver. The drug is taken orally as a pill, typically twice daily, making it more convenient than intravenous treatments^[4].

Clinical trials have demonstrated that ruxolitinib can help patients whose disease did not respond adequately to corticosteroids. Studies have shown improvement in liver enzyme levels and other measures of liver function in some patients taking this medication. The drug has progressed through Phase III clinical trials, which compare its effectiveness to standard treatments in large numbers of patients. Based on positive results, ruxolitinib has received approval for use in patients with chronic graft versus host disease who have failed to respond to one or two prior lines of therapy^[13].

Common side effects of ruxolitinib include lowered blood counts, particularly platelets and red blood cells, which require monitoring through regular blood tests. Patients may experience increased infection risk, bruising, or fatigue. Despite these potential complications, many patients tolerate the medication well, and it offers an important option for those who have not responded to traditional immunosuppressive therapy^[13].

Ibrutinib, originally developed to treat certain blood cancers, works by blocking an enzyme called Bruton’s tyrosine kinase. This enzyme plays a role in activating immune cells, particularly B cells, which can contribute to chronic graft versus host disease. By inhibiting this enzyme, ibrutinib reduces the activity of these immune cells and decreases inflammation. Like ruxolitinib, ibrutinib is taken orally, usually once daily^[13].

Clinical trials investigating ibrutinib for chronic graft versus host disease have included patients with liver involvement. Results have shown that some patients experience improvement in liver enzyme levels and reduction in other symptoms of the disease. The medication has been studied in Phase II and Phase III trials, which examine both its safety and effectiveness. Based on positive findings, ibrutinib has received approval for treating chronic graft versus host disease in patients who have not responded adequately to other treatments^[13].

Side effects of ibrutinib can include increased bleeding risk due to effects on platelet function, irregular heart rhythms in some patients, muscle and joint pain, and increased infection risk. Patients taking ibrutinib require monitoring for these complications, though many people tolerate the medication well enough to continue therapy long-term^[13].

Belumosudil represents a novel approach to treating chronic graft versus host disease by inhibiting an enzyme called Rho-associated coiled-coil kinase 2 (ROCK2). This enzyme influences multiple processes involved in chronic graft versus host disease, including immune cell activation, inflammation, and the development of fibrosis or scarring in affected organs. By blocking ROCK2, belumosudil can reduce both the inflammatory and fibrotic aspects of the disease, which may be particularly beneficial for liver involvement^[13].

Clinical trials of belumosudil have progressed through Phase II studies demonstrating effectiveness in patients whose chronic graft versus host disease did not respond to two or more prior treatments. Patients in these trials showed improvement in liver function tests along with benefits in other affected organs. The medication is taken orally twice daily, providing convenient administration. Based on trial results showing positive safety profiles and clinical improvement, belumosudil has received approval for use in patients with chronic graft versus host disease who have failed at least two prior lines of therapy^[13].

Common side effects of belumosudil include fatigue, nausea, diarrhea, and muscle cramps. Some patients experience elevated liver enzymes, which requires monitoring, though this side effect is generally manageable. The medication offers an important option for patients with difficult-to-treat disease, including those with liver involvement^[13].

Axatilimab, an emerging therapy being studied in clinical trials, represents a different approach by blocking a receptor called colony-stimulating factor 1 receptor (CSF-1R). This receptor is found on certain immune cells called macrophages, which can contribute to inflammation and fibrosis in chronic graft versus host disease. By blocking CSF-1R, axatilimab reduces the activity of these cells and may help control disease in multiple organs including the liver^[13].

Early-phase clinical trials of axatilimab have shown promising results in patients with chronic graft versus host disease that has not responded to other treatments. The medication is given as an intravenous infusion, typically once every two weeks. Researchers are particularly interested in its potential to address the fibrotic aspects of chronic graft versus host disease, which can be difficult to treat with other medications. Studies are ongoing to determine the optimal dose and treatment schedule^[13].

Because axatilimab is still in earlier phases of clinical development, information about its full safety profile and effectiveness continues to emerge. Patients interested in this treatment would need to participate in clinical trials, which may be available at specialized transplant centers in the United States and other countries. Trial eligibility typically requires that patients have received and not responded adequately to at least two prior lines of therapy for chronic graft versus host disease^[13].

Other innovative approaches being explored in clinical trials include mesenchymal stem cell therapy, which involves infusing specially cultured stem cells that may help repair damaged tissue and reduce inflammation. Studies have investigated whether these cells can help patients with steroid-refractory chronic graft versus host disease, including those with liver involvement. While results have been mixed, some patients have shown improvement, and research continues to refine this approach^[8].

Researchers are also studying various monoclonal antibodies that target specific immune system components. These include antibodies against the interleukin-2 receptor, which is present on activated immune cells, and other targets involved in the immune attack on transplant recipients’ organs. Some of these agents have shown promise in early-phase trials, though larger studies are needed to establish their role in treatment^[8].

Most Common Treatment Methods

• Corticosteroid Therapy
  • Prednisone and methylprednisolone serve as the mainstay of treatment, suppressing immune system activity to reduce liver inflammation and damage^[6]
  • Doses typically range from one to two milligrams per kilogram daily, with gradual tapering based on response^[8]
  • Treatment duration often extends from one to three years, requiring careful monitoring for side effects including bone loss, diabetes, and muscle weakness^[12]
• Calcineurin Inhibitor Treatment
  • Cyclosporine and tacrolimus block specific immune activation pathways, often combined with corticosteroids^[8]
  • Blood level monitoring ensures therapeutic dosing while avoiding kidney toxicity and other complications^[8]
  • These medications form part of both prevention strategies and active treatment protocols^[8]
• JAK Inhibitor Therapy
  • Ruxolitinib blocks Janus kinase proteins that transmit inflammatory signals, taken orally twice daily^[4]
  • Approved for patients who have not responded adequately to one or two prior treatment lines^[13]
  • Clinical trials have shown improvement in liver enzyme levels and overall disease control^[13]
• Bruton’s Tyrosine Kinase Inhibition
  • Ibrutinib reduces immune cell activation by blocking a key enzyme in B cell signaling pathways^[13]
  • Taken once daily as an oral medication for patients with inadequate response to other treatments^[13]
  • Phase III trials have demonstrated effectiveness in chronic graft versus host disease with liver involvement^[13]
• ROCK2 Inhibitor Treatment
  • Belumosudil targets inflammation and fibrosis by blocking Rho-associated coiled-coil kinase 2^[13]
  • Approved for patients who have failed at least two prior therapy lines, taken orally twice daily^[13]
  • Addresses both inflammatory and scarring components of chronic graft versus host disease^[13]
• Extracorporeal Photopheresis
  • White blood cells are collected, treated with light-sensitive medication, exposed to ultraviolet light, and returned to the body^[8]
  • Helps patients who cannot tolerate high-dose systemic medications or have treatment-resistant disease^[8]
  • Typically performed on consecutive days every two to four weeks at specialized centers^[8]